Press "Enter" to skip to content

American Biotech Regeneron Pharmaceuticals Inc. Performed Better

Regeneron Pharmaceuticals Inc. shares inched 0.42% higher to $505.36 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.14% to 4,208.12 and the Dow Jones Industrial Average DJIA rising 0.07% to 34,600.38.

Regeneron Pharmaceuticals Inc. closed $159.28 below its 52-week high ($664.64), which the company achieved on July 20th. The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Johnson & Johnson JNJ rose 0.40% to $166.20, Novartis AG ADR NVS rose 0.87% to $88.89, and Amgen Inc. AMGN rose 0.68% to $235.16.

Regeneron Pharmaceuticals Inc trading volume (678,685) remained 134,393 below its 50-day average volume of 813,078. This was the stock’s third consecutive day of gains. Total revenues increased by 38% to $2.529 billion in the first quarter of 2021, compared to $1.828 billion in the first quarter of 2020. Total revenues excluding REGEN-COV increased by 20% to $2.200 billion in the first quarter of 2021, compared to the first quarter of 2020.

Total revenues also include collaboration revenues(2) of $754 million in the first quarter of 2021, compared to $528 million in the first quarter of 2020. Sanofi collaboration revenue increased primarily due to the Company’s share of profits from the commercialization of antibodies, which were $261 million in the first quarter of 2021, compared to $171 million in the first quarter of 2020.The change in the Company’s share of profits from the commercialization of antibodies was primarily driven by higher Dupixent profits. In the first quarter of 2021, the Company also recorded Roche collaboration revenue of $67 million in connection with the Company’s share of gross profits from sales of the casirivimab with imdevimab antibody cocktail.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *